SNY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 30, 2026Sponsor estimate | NCT07457580Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)Sanofi · Type 1 Diabetes | SNYLead | No phase registered | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07457580Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)Sanofi · Type 1 DiabetesRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT01973881Quantitative MRI for MyelofibrosisUniversity of Michigan Rogel Cancer Center · MyelofibrosisRecruitingSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT06832865ELISA in Relapsed/Refractory MMMassachusetts General Hospital · Relapsed Refractory Multiple Myeloma (RRMM)RecruitingPFECollaboratorSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimateNo phase registeredNCT04743609RSV Burden in Outpatient and Hospital SettingsAssociation Clinique Thérapeutique Infantile du val de Marne · RSV InfectionRecruitingSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 2NCT06958536A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseSanofi · Crohn's DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimatePhase 2NCT06500702A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary...Sanofi · Focal Segmental GlomerulosclerosisRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 7, 2027Sponsor estimate | NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi · Sickle Cell Disease | SNYLead | Phase 3 | Recruiting | Locked | Locked | Locked |
| Jan 19, 2027Sponsor estimate | NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsSanofi · Solid Tumor | SNYLead | Phase 1/Phase 2 | Recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT07838038Effect of Messaging on Pragmatic Outcomes Within an Integrated Healthcare SystemKaiser Permanente · Covid-19 Vaccination | SNYCollaborator | No phase registered | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 7, 2027Sponsor estimatePhase 3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi · Sickle Cell DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2027Sponsor estimatePhase 1/Phase 2NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsSanofi · Solid TumorRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimateNo phase registeredNCT07838038Effect of Messaging on Pragmatic Outcomes Within an Integrated Healthcare SystemKaiser Permanente · Covid-19 VaccinationRecruitingSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 9, 2027Sponsor estimate | NCT07170917Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaSanofi · Hidradenitis Suppurativa | SNYLead | Phase 2 | Recruiting | Locked | Locked | Locked |
| Feb 11, 2027Sponsor estimate | NCT06984627A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseSanofi · Graves' Disease | SNYLead | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 9, 2027Sponsor estimatePhase 2NCT07170917Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaSanofi · Hidradenitis SuppurativaRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 11, 2027Sponsor estimatePhase 2NCT06984627A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseSanofi · Graves' DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.